Avenue Biosciences Company Profile

Background

Avenue Biosciences is a transatlantic biotechnology company dedicated to accelerating the discovery and development of protein biologics, ensuring that no life-saving therapy is hindered by production barriers. With operations in Helsinki, Finland, and Palo Alto, California, the company has developed a protein engineering platform that combines organic biology and machine learning to enhance protein production. This proprietary method is rooted in years of scientific research from the University of Helsinki.

Key Strategic Focus

Avenue Biosciences focuses on optimizing protein production systems, from mRNA therapies to synthetic proteins. Their platform simultaneously analyzes over 5,500 naturally occurring and synthetic signal peptides, delivering significant improvements in protein yield—up to 500% in external validations. This technology is particularly effective for difficult-to-express proteins that often impede development.

Financials and Funding

In October 2024, Avenue Biosciences secured a $2.5 million seed financing round led by Voima Ventures, with additional participation from Inventure and U.S. angel investors. The funding aims to accelerate the development of their platform, designed to improve the efficiency of protein production in the biopharmaceutical industry.

Pipeline Development

The company's lead product is a high-throughput signal peptide engineering platform. As of June 2025, Avenue Biosciences presented this technology at the BIO International Convention, indicating readiness for commercial sales.

Technological Platform and Innovation

Avenue Biosciences' platform is a unique combination of high-throughput chemistry and synthetic biology, powered by machine learning and AI algorithms. It is the most powerful solution to engineering N-terminal signal peptides, an element significantly underutilized in protein biologics. This technology enhances any protein production system, from protein biologics and biosimilars to any mammalian protein-based biotechnology tools.

Leadership Team

Tero-Pekka Alastalo, MD, PhD: CEO and co-founder with over 13 years of life science startup experience and previous exits. He has more than a decade of research and clinical experience and is based in Silicon Valley, CA.

Katja Rosti, PhD, eMBA: COO and co-founder with over 20 years of experience in the protein biology industry, both in academia and major biotech companies, holding scientific and commercial leadership roles. She is the operational lead and co-inventor of Avenue Biosciences’ core technology, based in Helsinki, Finland.

Veli-Pekka Jaakola, PhD: CTO with over 20 years in international biotechnology and extensive academic experience in biochemistry, structural biology, and protein screening. He has worked with membrane proteins, G protein-coupled receptors (GPCRs), and antibody tool development.

Juulia Simonen: Director of Brand & Communications with over 10 years of experience in building brand awareness, PR, and thought leadership for rapidly growing companies in life sciences, health technologies, and finance.

Anton Klåvus: Data Science Director with over 5 years of experience building machine learning applications and handling data in life science startups, academia, and larger companies. His work spans both development and customer-facing roles, bridging science and industry.

Leadership Changes

In May 2025, Avenue Biosciences appointed Veli-Pekka Jaakola as Chief Technology Officer. Jaakola brings over two decades of international biotechnology experience, with extensive academic expertise in biochemistry, structural biology, and protein screening.

Competitor Profile

Market Insights and Dynamics

The biopharmaceutical industry is experiencing rapid growth, driven by advancements in protein-based biologics and the increasing demand for efficient protein production systems. The integration of machine learning and AI in protein engineering is revolutionizing therapeutic development, offering significant improvements in yield and quality.

Competitor Analysis

Key competitors in the protein engineering space include:

AbSci: Specializes in synthetic biology and protein expression technologies, focusing on complex biologics production.

Ginkgo Bioworks: Offers organism engineering services, including protein production optimization, leveraging extensive automation and data analytics.

Codexis: Develops protein engineering solutions for biotherapeutics and industrial enzymes, utilizing proprietary platforms for enzyme optimization.

Strategic Collaborations and Partnerships

Avenue Biosciences has engaged in several strategic initiatives:

BioTools Innovator Accelerator Program: In June 2025, the company was selected for this prestigious four-month accelerator program, offering tailored mentorship, investor exposure, and networking opportunities.

StartX Community: In October 2024, Avenue Biosciences joined StartX, a Silicon Valley-based community for Stanford-affiliated entrepreneurs, providing access to talent and resources to grow its presence in the North American biotechnology market.

Advisory Board Formation: In October 2024, the company established an advisory board comprising distinguished experts in biotechnology and academia, including Jens Vogel, Sofia Lund, Gary Zweiger, and Ville Paavilainen, to strengthen operations with a wealth of experience from biopharmaceuticals and life sciences.

Operational Insights

Avenue Biosciences' strategic positioning in both Helsinki and Palo Alto allows it to leverage Nordic scientific expertise and access the North American market. The company's focus on optimizing protein production systems addresses a critical bottleneck in biopharmaceutical development, providing a competitive advantage in the rapidly evolving biotech landscape.

Strategic Opportunities and Future Directions

With the successful seed funding and participation in accelerator programs, Avenue Biosciences is poised to scale its AI-enhanced protein engineering platform. The company aims to expand its market presence, forge strategic partnerships, and continue innovating to meet the growing demand for efficient protein production solutions in the biopharmaceutical industry.